Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company based in San Diego, specializing in the development of novel therapies for metabolic and endocrine disorders. Focused on creating first-in-class or best-in-class treatments, Viking's research leverages its deep expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
Viking's pipeline includes three main compounds currently in clinical trials. VK2809, a selective thyroid hormone receptor beta agonist, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Recent data from a Phase 2b VOYAGE study showed that VK2809 achieved both its primary and secondary endpoints, demonstrating significant reductions in liver fat content and improvements in fibrosis and NASH resolution over a 52-week treatment period.
The company is also advancing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is being developed for the treatment of metabolic disorders such as obesity. Phase 1 and 2 trials have indicated promising efficacy and safety profiles, with significant reductions in body weight observed in treated patients. Viking is evaluating both subcutaneous and oral formulations of VK2735, aiming to enhance patient convenience and expand market opportunities.
In the realm of rare diseases, Viking is developing VK0214, a selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD). Currently in a Phase 1b clinical trial, VK0214 has shown potential benefits in treating the adrenomyeloneuropathy (AMN) form of X-ALD.
Financially, Viking reported a strong cash position of $963 million as of March 31, 2024, following a public offering of common stock. The company's strategic focus on advancing its clinical programs, coupled with its robust financial health, positions it well for future growth and development.
For more information, please visit Viking Therapeutics' website.
Viking Therapeutics, Inc. (NASDAQ: VKTX) reported its financial results for Q1 2021, revealing a net loss of $14.0 million, or $0.19 per share, compared to a $9.7 million loss in Q1 2020. The company continues its Phase 2b VOYAGE trial for VK2809 in NASH, with enrollment expected to complete in H2 2021. The cash balance stands at approximately $242 million, providing a strong runway for its clinical programs. Key advancements include ongoing trials for VK0214, aimed at treating X-ALD, with a Phase 1b study anticipated this summer.
Viking Therapeutics (NASDAQ: VKTX) announces it will release its Q1 2021 financial results after market close on April 28, 2021. A conference call to discuss these results and corporate updates will commence at 4:30 p.m. ET on the same day. Interested parties can participate via phone or listen online through the company's webcast. Viking is focused on developing therapies for metabolic and endocrine disorders, with key projects including VK2809 for NASH and VK0214 for X-ALD.
Viking Therapeutics announces that CEO Brian Lian, Ph.D., will present at the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021. His presentation is scheduled for April 14 from 3:45 – 4:25 p.m. Eastern. The company focuses on developing innovative therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK0214 is also in a Phase 1 trial for X-linked adrenoleukodystrophy (X-ALD). For more information, visit vikingtherapeutics.com.
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in three upcoming investor conferences. The first is the HC Wainwright Global Life Science Conference on March 9-10, 2021, where a corporate presentation will be available online. This is followed by the 33rd Annual Roth Conference on March 15-17 and the Oppenheimer's 31st Annual Healthcare Conference on March 16-18, with presentations and meetings scheduled. The company focuses on therapies for metabolic disorders, including its drugs VK2809 and VK0214, currently in clinical trials.
Viking Therapeutics (NASDAQ: VKTX) reported its fourth quarter and full-year 2020 financial results, revealing a net loss of $10.9 million for Q4, up from $7.5 million in Q4 2019. The total net loss for 2020 was $39.5 million, compared to $25.8 million in 2019. R&D expenses surged to $31.9 million, driven by clinical trial costs. The company maintains a strong balance sheet with $248.4 million in cash. Viking's ongoing VOYAGE trial for VK2809 and progress in the VK0214 program highlight its focus on metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) will report its financial results for Q4 and year-end 2020 after market close on February 17, 2021. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and corporate updates. Investors can participate by dialing (844) 850-0543 or (412) 317-5199, and a telephone replay will be available until February 24, 2021. Viking is focused on metabolic and endocrine disorder therapies, with ongoing clinical programs for VK2809 and VK0214.
On January 6, 2021, Viking Therapeutics (NASDAQ: VKTX) announced the promotion of Greg Zante to Chief Financial Officer and Marianne Mancini to Chief Operating Officer. Zante brings nearly 25 years of experience in financial management and previously served as Senior Vice President of Finance at Viking. Mancini has over 30 years of experience, focusing on clinical trials, and was previously Senior Vice President of Clinical Operations. These promotions reflect their significant contributions to the company, particularly in advancing therapies for metabolic disorders including non-alcoholic steatohepatitis (NASH).
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its CEO, Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available online starting on January 11. Viking Therapeutics specializes in developing innovative therapies for metabolic and endocrine disorders. Key programs include VK2809, targeting non-alcoholic steatohepatitis (NASH) and fibrosis, and VK0214, aimed at X-linked adrenoleukodystrophy (X-ALD), indicating strong potential in the biopharmaceutical landscape.
Viking Therapeutics (NASDAQ: VKTX) is set to present at the Stifel Healthcare Conference 2020, with CEO Brian Lian, Ph.D., delivering insights on the company's innovative therapies for metabolic and endocrine disorders. The virtual event will occur from November 16-18, 2020, with Viking's presentation scheduled for 11:40 a.m. PST on November 17, 2020. Investors can access the live webcast on Viking's website, where a replay will also be available post-conference. Viking is advancing its clinical programs, which include VK2809 and VK0214, targeting significant health issues.
Viking Therapeutics (NASDAQ: VKTX) reported its Q3 financial results with a net loss of $9.3 million, or $0.13 per share, compared to a loss of $5.7 million last year. Key developments include ongoing enrollment in the Phase 2b VOYAGE study for VK2809 targeting non-alcoholic steatohepatitis (NASH) and the initiation of a Phase 1 trial for VK0214, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The company ended the quarter with approximately $255 million in cash, supporting further clinical advancements despite challenges posed by the COVID-19 pandemic.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
What is the focus of Viking Therapeutics, Inc.?
What are the main compounds in Viking's clinical pipeline?
What recent achievements has Viking Therapeutics reported?
What financial condition is Viking Therapeutics currently in?
What are the potential treatments being developed by Viking for metabolic disorders?
How does VK2735 work?
What is VK0214 targeting?
What significant clinical milestones has VK2809 achieved?
How is Viking Therapeutics funded for its operations?
Where can I get more information about Viking Therapeutics?
